NAREB Partners

Institut Pasteur (IP)

Paris, France

Professor Brigitte Gicquel 

 

Role in NAREB

  • Coordinator of the project
  • Leader of WP1 Screening of candidate therapeutic molecules & WP8 Management and Coordination
  • Identification of the targets and natural resistance to leads identified for further coupling to nanoparticles
  • Study of the microbial and host responses to the drugs associateonot to nanoparticles

Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA)

Grenoble, France

Fabrice Navarro

 

Role in NAREB

  • Leader of WP2 design of smart nanocarriers with antibacterial activity.
  • Development of drug-loaded lipid-based nanoparticles for the controlled delivery to MDR-TB and MRSA infections.

University Utrecht (UU)

Utrecht, The Netherlands

René van Nostrum

 

Role in NAREB

  • Development of drug-loaded polyester nanoparticles for the controlled delivery to MDR-TB and MRSA infections.

PROCARTA Biosystems Limited (PROCARTA)

Norwich, United Kingdom

Michael Mc Arthur

 

Role in NAREB

  • Development of novel oligonucleotide antimicrobials to treat Gram-positive infections caused by MRSA and Mycobacterium tuberculosis.
  • Development of novel, nanoparticulate delivery systems.

Universidad de Zaragoza (UNIZAR)  

Zaragoza, Spain

Jose Ainsa & Jesus Martinez de la Fuente

 

Role in NAREB

  • Leader of WP3 Diagnostic and activity tests in vitro
  • Development of drug-loaded polysaccharidic-based nanoparticles for the controlled delivery to MDR-TB and MRSA infections
  • Cytotoxicity test of nanoparticles against cell lines in vitro.
  • Antimicrobial activity test of encapsulated drugs against S. aureus and M. tuberculosis in vitro.

Narodowy Instytut Lekow (NIL)

Warsaw, Poland

Waleria Hryniewicz & Joanna Empel

 

Role in NAREB

  • Creation and delivery of a collection of pan-susceptible and drug resistanS. aureus isolates.
  • Antimicrobial activity test of drug-containing nanoparticles with S. aureus.

Forschungszentrum Borstel (FZB)

Borstel, Germany

Ulrich Schaible

 

Role in NAREB

  • Bio-distribution and treatment efficacy studies of anti-TB drug-loaded nanoparticles in different murine TB models using in vivo and ex vivo bio-imaging and confocal microscopy.

BIOASTER (BIOASTER)

Lyon, France

Andrea Tamellini & Abdessalem Rekiki

 

Role in NAREB

  • Leader of WP4 In vivo efficacy tests and biodistribution
  • Evaluation of in vivo efficacy and fluorescent imaging biodistribution of drug-loaded nanoparticles in murine MRSA models.
  • Evaluation of pre-clinical safety of drug-loaded nanoparticles on human leukocytes in vivo

Department of Health (DH-MHRA)

London, United Kingdom

Mei Mei Ho

 

Role in NAREB

  • Establishment and coordination of the Product Development Team for the management of the drug development process and identification of potential regulatry issues relevant along a preclinical tearly phase clinical development pathway.

GlaxoSmithKline Investigation y Desarrollo (GSK)

Madrid, Spain

Lluis Ballel-Pages & Pablo Gamallo

 

Role in NAREB

  • Anti-tubercular lead sourcing fonano-encapsulation.
  • In vivo efficacy evaluatioof drug-loaded nanoparticles in murine TB models.

CORIS BioConcept (CORIS)

Gembloux, Belgium

Pascal Mertens & Laetitia Avrain

 

Role of Coris in NAREB

  • Development of new diagnostic tests for detecting bacteria and resistance markers.
  • Evaluation of drug-loaded nanoparticles with quantitative PCR for specific bacteria detection.

Nanoimmunotech (NIT)

Spain

Daniel Perez

 

Role in NAREB

  • Leader of WP5 Safety of developed nanosystems.
  • Physicochemical and biological characterization of the nanoparticles: sterility and endotoxin content of the generated nanoparticles, interaction with cells to validate cell targeting and hemocompatibility to validate administration route, biodistribution assay of the drug-loaded nanoparticles in collaboration with SINTEF. 
  • Safety evaluation: Toxic profile in vitro and in vivo of the prototypes. In vivo experiment for immunotoxicity assessment.

Stiftelsen Sintef (SINTEF)

Norway

Ruth Schmid

 

Role in NAREB

  • Development of antibiotics-loaded poly(alkylcyanoacrylate)(PACA) nanoparticles for the controlled delivery to MDR-TB and MRSA infections.
  • Drug loading and drug release studies in complex media by MS-based methods.
  • Activity screening for MRSA drugs.
  • Activity tests with S. aureus biofilms.
  • Biodistribution of drug-loaded nanoparticles in tissues with MS-imaging.

Inserm Transfert (IT)

Paris, France

Barbara Cagniard

 

Role of IT in NAREB

  • Leader of WP7 Dissemination, exploitation, training.
  • Support to project management.

Kuecept Limited (KU)

Hertfordshire, United Kingdom

Mark Saunders & Cristina Freire

 

Role in NAREB

  • Leader of WP6 Translational regulatory aspects and Clinical development Plan
  • Development of I.V. formulations of selected drug-loaded nanoparticles for in vivo efficacy testing.
  • Coordination of the Clinical development Plan to prepare the transition from preclinical research to the clinical development program.

eu-fev2014-2

The NAREB project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 604237.